morningstar.com
Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment - Morningstar
This trial targets fibrotic narrowings (strictures) in Crohn’s disease — a common complication without approved drug treatments — so positive results could change care options and reduce the need for surgery.
The study is a mid-stage (Phase 2b) test of an oral investigational drug, ontunisertib, with a practical scope-passage endpoint at 24 weeks and follow-up to 52 weeks.
Adults with Crohn’s disease (especially those with fibrostenotic disease), gastroenterologists/IBD clinicians, and researchers in IBD drug development.
What To Know
Agomab and the FDA have agreed on the design of a Phase 2b trial testing the oral investigational drug ontunisertib in adults with Crohn’s disease who develop intestinal narrowings (fibrotic strictures).
The randomized, placebo-controlled study plans to enroll up to ~320 patients, assess whether a scope can pass the narrowed segment at 24 weeks as a primary practical endpoint, and follow participants to 52 weeks for longer-term outcomes. The protocol has been filed with the FDA and cleared U.S.
central ethics review; Health Canada approval and other regional submissions were also reported. First dosing was expected in the second half of 2026. This is a company-announced Phase 2b trial design agreement and not a report of positive clinical results or approval.
The trial focuses on a common Crohn’s complication — fibrotic narrowings (strictures) — for which there are currently no approved drug treatments. The scope-passage check at 24 weeks is a practical, disease-relevant way to evaluate improvement in narrowing.
Enrollment, geographic rollout, and final outcomes will determine whether ontunisertib is effective and safe for this indication.
How this may affect patients: If the drug proves effective in reducing strictures, it could offer a non-surgical treatment option for people with fibrostenotic Crohn’s disease; however, benefits and risks are unknown until trial results are available.
Adults with Crohn’s disease, especially those with or at risk for fibrostenotic strictures; gastroenterologists and IBD clinicians; clinical researchers tracking IBD drug development.
This report summarizes a company press/financial wire announcement about trial design and regulatory clearances; it does not present trial data, safety results, or regulatory approvals. The practical endpoint (scope passage) is meaningful clinically but will need correlation with symptoms and longer-term outcomes. Timelines and enrollment can change.
